Skip to content Skip to footer
Subscribe Now
PharmaShots' Key Highlights of First Quarter 2022
INSIGHTS+

PharmaShots’ Key Highlights of First Quarter 2022

The first quarter of 2022 highlights the approvals, clinical data & acquisitions. There are major alliances in this quarter which include Biocon acquired Viatris’ biosimilars assets for ~$3.335B, Stryker signed a definitive agreement to acquire Vocera Communications for ~$3.09B, Biohaven acquire Channel Biosciences for ~$3B The first quarter of the year also showcases regulatory events…
March 31, 2022

Read more

PharmaShots Interview Seattle Children’s Research Institute’ Fred David Mast Shares Insight on Nanobodies for the Prevention of COVID-19
VIEWPOINTS

PharmaShots Interview: Seattle Children’s Research Institute’ Fred David Mast Shares Insight on Nanobodies for the Prevention of COVID-19

In an interview with PharmaShots, Fred David Mast, Senior Research Scientist at Seattle Children’s Research Institute shared his views on the study demonstrating that Nanobodies could be an exceptional resource for superior COVID-19 protective and therapeutic interventions. The results of this study were published in E-life Shots: Seattle Children’s Research Institute’s scientists collaborated with researchers from Rockefeller University to investigate the…
March 31, 2022

Read more

Exclusive_Jeremiah Robison_2022
EXCLUSIVE

Exclusive Interview with PharmaShots: Jeremiah Robison of Cionic Shares Insight on Neural Sleeve for Neurological Disorders

In an interview with PharmaShots, Jeremiah Robison, Founder, and CEO at Cionic shared his views on the US FDA’s clearance of Neural Sleeve for patients with cerebral palsy, MS, stroke, and other disorders Cionic’s Neural Sleeve has received the US FDA clearance for functional electrical stimulation to assist in gait for patients with foot drop and leg muscle weakness. The lightweight…
March 30, 2022

Read more

PharmaShots Interview Eli Lilly’s Eric Pearlman Shares Insight on Emgality (galcanezumab-gnlm) for the Treatment of Episodic Migraine
VIEWPOINTS

PharmaShots Interview: Eli Lilly’s Eric Pearlman Shares Insight on Emgality (galcanezumab-gnlm) for the Treatment of Episodic Migraine

In an interview with PharmaShots, Eric Pearlman, Associate Vice President, Global & US Medical Affairs at Eli Lilly shared his views on the initiation of the patients enrollment in P-IV (CHALLENGE-MIG) head-to-head trial of Emgality for episodic migraine in adults Shots: The company initiate the patients' enrollment for the P-IV (CHALLENGE-MIG) head-to-head trial to evaluate the efficacy and safety of Emgality vs Nurtec ODT…
March 29, 2022

Read more

PharmaShots Interview Takeda’s Elke Walter & Derek Wallace Share Insights on TAK-003 for Dengue & Zika Viruses
VIEWPOINTS

PharmaShots Interview: Takeda’s Elke Walter & Derek Wallace Share Insights on TAK-003 for Dengue & Zika Viruses

In an interview with PharmaShots, Elke Walter, Senior Director, Global Zika Program Lead & Derek Wallace, Vice President, Global Dengue Program Lead at Takeda share their views on TAK-003 & highlighted 10 presentations from dengue and zika programs at ASTMH Shots: The company reported a cumulative safety assessment included long-term safety data from the five…
March 23, 2022

Read more

PharmaShots Interview Astellas’ John C. Hairston & Gabriel P. Haas Share Insights on Xtandi (enzalutamide) for the Treatment of Prostate Cancer
VIEWPOINTS

PharmaShots Interview: Astellas’ John C. Hairston & Gabriel P. Haas Share Insights on Xtandi (enzalutamide) for the Treatment of Prostate Cancer

In an interview with PharmaShots, John C. Hairston, Sr. Medical Director, Oncology US Medical Affairs & Gabriel P. Haas, Senior Medical Director, Oncology Development Medical Sciences at Astellas share their views on the data of Xtandi (enzalutamide) over Active Surveillance for Localized Prostate Cancer Shots: The P-II (ENACT) study evaluates enzalutamide as monothx. vs active…
March 22, 2022

Read more

PharmaShots Interview Tillotts Pharma’s Adrian Hill & Christian Weidenfeller Share Insights on Dificlir (fidaxomicin) for the Treatment of Clostridioides Difficile Infection
VIEWPOINTS

PharmaShots Interview: Tillotts Pharma’s Adrian Hill & Christian Weidenfeller Share Insights on Dificlir (fidaxomicin) for the Treatment of Clostridioides Difficile Infection

In an interview with PharmaShots, Adrian Hill, Head of Commercial Operations & Christian Weidenfeller, Global Head of Medical Affairs Anti-Infectives at Tillotts Pharma share their views on the ESCMID recommendation for Dificlir (fidaxomicin) to treat Clostridioides Difficile Infection Shots: ·        Clostridioides difficile infection (CDI) is the leading cause of hospital-acquired infection · …
March 21, 2022

Read more

Load more